ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 Study
Annals of Oncology
◽
10.1093/annonc/mdv514.09
◽
2015
◽
Vol 26
◽
pp. viii5
Author(s):
M. Maio
◽
A. Covre
◽
S. Coral
◽
G. Amato
◽
P. Taverna
◽
...
Keyword(s):
Metastatic Melanoma
◽
Second Generation
◽
Phase Ib
◽
Hypomethylating Agent
◽
Dna Hypomethylating Agent
Download Full-text
Related Documents
Cited By
References
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 study.
Journal of Clinical Oncology
◽
10.1200/jco.2016.34.15_suppl.tps9595
◽
2016
◽
Vol 34
(15_suppl)
◽
pp. TPS9595-TPS9595
◽
Cited By ~ 1
Author(s):
Anna Maria Di Giacomo
◽
Alessia Covre
◽
Pietro Taverna
◽
Sandra Coral
◽
Giovanni Amato
◽
...
Keyword(s):
Metastatic Melanoma
◽
Second Generation
◽
Phase Ib
◽
Hypomethylating Agent
◽
Dna Hypomethylating Agent
Download Full-text
Abstract 4076: SGI-110, a novel subcutaneous (SQ) second generation DNA hypomethylating agent achieves improved pharmacodynamics (PD), safety and pharmacokinetics (PK) in comparison to IV decitabine in a non-human primate in vivo study
10.1158/1538-7445.am2012-4076
◽
2012
◽
Cited By ~ 2
Author(s):
Pietro Taverna
◽
Jason Scholl
◽
Chongtie Shi
◽
Aram Oganesian
◽
Sanjeev Redkar
◽
...
Keyword(s):
Second Generation
◽
In Vivo Study
◽
Hypomethylating Agent
◽
Dna Hypomethylating Agent
◽
Human Primate
Download Full-text
465 SGI-110, a Novel Second Generation DNa Hypomethylating Agent, Enhances Sorafenib Activity and Alters Methylation Signature of HCC Cell Lines
European Journal of Cancer
◽
10.1016/s0959-8049(12)72263-3
◽
2012
◽
Vol 48
◽
pp. 144
◽
Cited By ~ 6
Author(s):
S. Jueliger
◽
J. Lyons
◽
M. Azab
◽
P. Taverna
Keyword(s):
Cell Lines
◽
Second Generation
◽
Hypomethylating Agent
◽
Dna Hypomethylating Agent
Download Full-text
Phase II Trial of Cisplatin Plus Decitabine, a New DNA Hypomethylating Agent, in Patients With Advanced Squamous Cell Carcinoma of the Cervix
American Journal of Clinical Oncology
◽
10.1097/00000421-200210000-00015
◽
2002
◽
Vol 25
(5)
◽
pp. 496-501
◽
Cited By ~ 50
Author(s):
Paula Pohlmann
◽
Luciane Pons DiLeone
◽
Anna Isabel Cancella
◽
Ana Paula F. Caldas
◽
Lissandra Dal Lago
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Phase Ii
◽
Squamous Cell
◽
Phase Ii Trial
◽
Advanced Squamous Cell Carcinoma
◽
Hypomethylating Agent
◽
Dna Hypomethylating Agent
Download Full-text
Clonal analysis of the malignant properties of B16 melanoma cells treated with the DNA hypomethylating agent 5-azacytidine
Clinical & Experimental Metastasis
◽
10.1007/bf01782479
◽
1988
◽
Vol 6
(3)
◽
pp. 185-200
◽
Cited By ~ 9
Author(s):
Deborah L. Trainer
◽
Thomas Kline
◽
Gary Hensler
◽
Russell Greig
◽
George Poste
Keyword(s):
Melanoma Cells
◽
Clonal Analysis
◽
B16 Melanoma
◽
B16 Melanoma Cells
◽
Hypomethylating Agent
◽
Dna Hypomethylating Agent
Download Full-text
Abstract 2947: Pharmacodynamic (PD) and pharmacokinetic (PK) results of the second-generation hypomethylating agent, SGI-110, in patients with hepatocellular carcinoma (HCC) after progression on sorafenib
10.1158/1538-7445.am2015-2947
◽
2015
◽
Cited By ~ 1
Author(s):
Anthony El-Khoueiry
◽
Mary F. Mulcahy
◽
Tanios Bekaii-Saab
◽
Richard Kim
◽
Crystal Denlinger
◽
...
Keyword(s):
Hepatocellular Carcinoma
◽
Second Generation
◽
Hypomethylating Agent
Download Full-text
A randomized phase Ib/II study of the selective small molecule Axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Annals of Oncology
◽
10.1093/annonc/mdz255.025
◽
2019
◽
Vol 30
◽
pp. v563
Author(s):
O. Straume
◽
J.B. Lorens
◽
G. Gausdal
◽
B.T. Gjertsen
◽
C. Schuster
Keyword(s):
Metastatic Melanoma
◽
Small Molecule
◽
Phase Ib
Download Full-text
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
Translational Oncology
◽
10.1016/j.tranon.2019.02.007
◽
2019
◽
Vol 12
(6)
◽
pp. 828-835
◽
Cited By ~ 21
Author(s):
Lu Si
◽
Xiaoshi Zhang
◽
Yongqian Shu
◽
Hongming Pan
◽
Di Wu
◽
...
Keyword(s):
Metastatic Melanoma
◽
Chinese Patients
◽
Second Line
◽
Second Line Therapy
◽
Phase Ib
◽
Line Therapy
Download Full-text
225. Updated Results of a Phase II Clinical Trial with a Second Generation, Gene-Modified, Immune-Enhanced, Oncolytic Herpes Virus in Unresectable Metastatic Melanoma
Molecular Therapy
◽
10.1016/s1525-0016(16)38583-5
◽
2009
◽
Vol 17
◽
pp. S88-S89
Keyword(s):
Clinical Trial
◽
Metastatic Melanoma
◽
Phase Ii
◽
Herpes Virus
◽
Second Generation
◽
Phase Ii Clinical Trial
◽
Herpès Virus
Download Full-text
Abstract CT129: HyPeR: A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with pembrolizumab (MK3475) in patients with refractory solid tumors
10.1158/1538-7445.am2020-ct129
◽
2020
◽
Author(s):
Dionysis Papadatos-Pastos
◽
Abhijit Pal
◽
Melek Akay
◽
Malaka Ameratunga
◽
Sanjena Mithra
◽
...
Keyword(s):
Solid Tumors
◽
Dose Escalation
◽
Second Generation
◽
Phase 1
◽
Hypomethylating Agent
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close